Presentations & Webinars

2019 TCT Late Breaking Oral Presentation of Phase 3 SIERRA Trial of Iomab-B

Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy for CAR-T

Iomab-B Phase 3 Oral Presentation at ASH 2018

CD33 Program Update – Actimab-A Post Phase 2 Results and Actimab-MDS Regulatory Update

Company Update - Next Generation Lymphodepletion Technology for CAR-T Conditioning

Iomab-B DMC Update Conference Call

Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Webcast

CD33 Program Expansion: Actimab-A + CLAG-M Conference Call

ASH 2017 Actimab-A Preliminary Phase 2 Results

ASH 2017 AWE Platform Results with Daratumumab

• « Previous
• 1
• 2
• 3
• 4
• 5
• Next »